Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Contrast Media & Molecular Imaging|December 6, 2018
Towards More Structure: Comparing TNM Staging Completeness and Processing Time of Text-Based Reports versus Fully Segmented and Annotated PET/CT Data of Non-Small-Cell Lung CancerRaphael Sexauer, Thomas Weikert, Kevin Mader, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2010
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CTDamian Wild, Andreas Wicki, Rosalba Mansi, et al.
Plos One|December 12, 2024
Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancerTarun Mehra, Judith E Lupatsch, Thibaud Koessler, et al.
Dermatology (Basel, Switzerland)|December 5, 2014
Vemurafenib-induced radiation recall dermatitis: case report and review of the literatureKatrin Conen, Katarzyna Mosna-Firlejczyk, Christoph Rochlitz, et al.
Plos One|April 4, 2024
Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancerTarun Mehra, Judith E Lupatsch, Thibaud Kössler, et al.
The Lancet. Oncology|November 17, 2012
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation studyChristoph Mamot, Reto Ritschard, Andreas Wicki, et al.
Journal for Immunotherapy of Cancer|August 18, 2016
Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapyViktor H Koelzer, Tobias Buser, Niels Willi, et al.
Cancer Medicine|April 21, 2023
Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entitiesTarun Mehra, Kanchan Dongre, Maria Boesing, et al.
EJNMMI Research|February 18, 2014
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumorsAndreas Wicki, Damian Wild, Vincent Prêtre, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2006
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targetingDamian Wild, Martin Béhé, Andreas Wicki, et al.
Pageof 9